Histone Deacetylase Inhibitors as Anticancer Drugs

Epigenetic Therapeutics: A New Weapon in the War Against Cancer

(2016) Nita Ahuja et al.   Annual Review of Medicine

Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models

(2016) RAJU CHELLURI et al.   ANTICANCER RESEARCH

Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential

(2016) Anna Kazanets et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals

(2016) Shao Wu et al.   BIOLOGICAL CHEMISTRY

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

(2016) Elena Ceccacci et al.   BRITISH JOURNAL OF CANCER

Molecular mechanism leading to SAHA-induced autophagy in tumor cells: evidence for a p53-dependent pathway

(2016) Leopold F. Fröhlich et al.   Cancer Cell International

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells

(2016) Taichi Takashina et al.   CANCER SCIENCE

Epigenome-based personalized medicine in human cancer

(2016) Wenji Yan et al.   Epigenomics

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

(2016) Sofia R. Gameiro et al.   Oncotarget

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases

(2016) Elizabeth E. Hull et al.   Biomed Research International

Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma

(2016) Mohamed Ashraf Khalil et al.   PLoS One

Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways

(2015) Jianbin Zhang et al.   Autophagy

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

(2015) Gabriele Greve et al.   BMC CANCER

Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies

(2015) C. M. Adams et al.   CANCER RESEARCH

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers

(2015) Srividya Bhaskara   CELL CYCLE

The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells

(2015) TOMAS GROH et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

MicroRNA-31 Is a Transcriptional Target of Histone Deacetylase Inhibitors and a Regulator of Cellular Senescence

(2015) Joon-Ho Cho et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

(2015) K.V. Woan et al.   Molecular Oncology

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat

(2015) Salma Afifi et al.   PHARMACOTHERAPY

Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail

(2015) Jutao Feng et al.   Cell Adhesion & Migration

Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites

(2015) Jessica A. Engel et al.   International Journal for Parasitology-Drugs and Drug Resistance

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Histone deacetylase inhibitors and cell death

(2014) Jing Zhang et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)

(2014) Sergio Valente et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis

(2014) Manjola Balliu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs

(2014) Fengdong Cheng et al.   JOURNAL OF IMMUNOLOGY

Generation of pluripotent stem cells without the use of genetic material

(2014) Akon Higuchi et al.   LABORATORY INVESTIGATION

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

(2014) Prithviraj Bose et al.   PHARMACOLOGY & THERAPEUTICS

Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells

(2013) Ming-Tsang Chiao et al.   Autophagy

Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells

(2013) Hui Yang et al.   BIOCHEMICAL PHARMACOLOGY

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia

(2013) I. M. Ghobrial et al.   BLOOD

Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration

(2013) Jin Zhu et al.   BRAIN RESEARCH

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression

(2013) M. A. Salvador et al.   CLINICAL CANCER RESEARCH

Histone deacetylases as targets for treatment of multiple diseases

(2013) Jinhua Tang et al.   CLINICAL SCIENCE

Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

(2013) Madeleine SQ Kortenhorst et al.   Epigenetics

Histone Deacetylase Inhibitors Potentiate Vesicular Stomatitis Virus Oncolysis in Prostate Cancer Cells by Modulating NF- B-Dependent Autophagy

(2013) L. Shulak et al.   JOURNAL OF VIROLOGY

Histone deacetylase 10 promotes autophagy-mediated cell survival

(2013) I. Oehme et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Noncoding RNA and Polycomb recruitment

(2013) N. Brockdorff   RNA

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

(2012) K.-T. Lin et al.   CLINICAL CANCER RESEARCH

New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy

(2012) I. Khan et al.   CLINICAL CANCER RESEARCH

The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment

(2012) M. Stiborova et al.   CURRENT MEDICINAL CHEMISTRY

Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8

(2012) Taeko Wada et al.   EMBO REPORTS

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed

(2012) Berkley E Gryder et al.   Future Medicinal Chemistry

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells

(2012) Chung Heon Ryu et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

(2012) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs

(2012) V. A. Moran et al.   NUCLEIC ACIDS RESEARCH

Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

(2012) N. Gammoh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming

(2012) Androniki Kretsovali et al.   Stem Cells International

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy

(2011) Min-Yu Chen et al.   CANCER

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

(2011) Victoria L. Luchenko et al.   CELL CYCLE

MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells

(2011) Patrick Brest et al.   ENDOCRINE-RELATED CANCER

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

(2011) Claudia P. Miller et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

The functional role of long non-coding RNA in human carcinomas

(2011) Ewan A Gibb et al.   Molecular Cancer

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

(2011) G. Dasmahapatra et al.   MOLECULAR CANCER THERAPEUTICS

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

(2011) M. Weller et al.   NEUROLOGY

Valproic acid overcomes hypoxia-induced resistance to apoptosis

(2011) ŠIMON CIPRO et al.   ONCOLOGY REPORTS

Histone Deacetylase Inhibition Enhances Self Renewal and Cardioprotection by Human Cord Blood-Derived CD34+ Cells

(2011) Ilaria Burba et al.   PLoS One

Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy

(2011) D. J. Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells

(2010) Jingyi Li et al.   Autophagy

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma

(2010) Yuan-Ling Liu et al.   Autophagy

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound  -phenylethyl isothiocyanate

(2010) Y. Hu et al.   BLOOD

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice

(2010) Amitabha Mazumder et al.   Clinical Lymphoma Myeloma & Leukemia

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

(2010) A. Scherpereel et al.   EUROPEAN RESPIRATORY JOURNAL

Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin

(2010) Akiko Hayashi et al.   INTERNATIONAL JOURNAL OF CANCER

Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells

(2010) Margaret A. Park et al.   MOLECULAR CANCER THERAPEUTICS

Highly Compacted Chromatin Formed In Vitro Reflects the Dynamics of Transcription Activation In Vivo

(2010) Guohong Li et al.   MOLECULAR CELL

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

(2010) M. Namdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antitumor Effects of a Combined 5-Aza-2'Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice

(2009) I. Ecke et al.   CANCER RESEARCH

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

miR-449a targets HDAC-1 and induces growth arrest in prostate cancer

(2009) E J Noonan et al.   ONCOGENE

Synergistic effect of trichostatin A and 5-aza-2′-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: A proteomic study

(2009) Daniela Cecconi et al.   PROTEOMICS

Inhibition of histone deacetylase1 induces autophagy

(2008) Meeyeon Oh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors

(2008) A. F. Setiadi et al.   CANCER RESEARCH

Acetylation Is Indispensable for p53 Activation

(2008) Yi Tang et al.   CELL

Promoter hypomethylation regulates CD133 expression in human gliomas

(2008) Kouichi Tabu et al.   CELL RESEARCH

Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

(2008) I. Oehme et al.   CLINICAL CANCER RESEARCH

Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors

(2008) Simone Fulda   CURRENT CANCER DRUG TARGETS

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

(2008) Stephanie Spange et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice

(2008) Rusty L. Montgomery et al.   JOURNAL OF CLINICAL INVESTIGATION

SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway

(2008) A Hrzenjak et al.   JOURNAL OF PATHOLOGY

Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications

(2008) Xiang-Jiao Yang et al.   MOLECULAR CELL

Sirtuins — novel therapeutic targets to treat age-associated diseases

(2008) Siva Lavu et al.   NATURE REVIEWS DRUG DISCOVERY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

(2008) Xiang-Jiao Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells

(2008) Guolin Chai et al.   PLoS One

A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy

(2008) I. H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

(2008) Elizabeth A. Griffiths et al.   SEMINARS IN HEMATOLOGY

Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells

(2007) Shan Gao et al.   LEUKEMIA RESEARCH